Supplementary Table 10A. Power calculation to estimate the required sample size to detect a genetic association between NOD2 rs5743293 / rs2066847 and the LacMan ratio
OR Sample Size
1.5 509
2.0 157
2.2 118
2.5 85
3.0 56
3.5 42
3.7 38
4.0 34
The table shows the estimated sample size required for a range of effect sizes (ORs)
The power calculation was performed using Quanto (http://hydra.usc.edu/gxe/) with the following assumptions:
(1) Case (High LacMan ratio) - Control (Normal LacMan ratio) matching with a 1: 5 ratio.
(2) α = 0.05 (2-sided), 1 - β = 0.8
(3) rs5743293 / rs2066847 minor allele frequency = 5%
(4)Additive genetic model.
(5)Outcome prevalence 11% (proportion of subjects with LacMan ratio > 0.03 in study cohort)
Supplementary Table 10B. Table from the report by Buhner et al.4 demonstrating the proportion of FDRs with normal and high LacMan ratio by NOD2 rs2066847 genotype
LacMan Ratio WT* rs2066847 carriers**
High 10 8
Normal*** 56 12
*WT - Non Carriers of rs2066847 risk variant
** rs2066847 carriers - Heterozygotes and homozygotes for rs2066847 risk variant
***Normal group had a LacMan ratio ≤ 0.03; high group had LacMan ratio > 0.03.
First Degree Relative of Crohn’s Disease affected individual (FDR)
Data in supplementary Table 10B was used to estimation an effect size from the report by Buhner et al.4 for NOD2 rs2066847. Logistic regression was used to estimate the Odds ratio (OR) for high LacMan ratio in NOD2 rs2066847 (3020InsC) carriers: Estimated OR 3.73 (95%
CI 1.22 - 11.49)
